AbbVie Inc.
ABBVHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, AbbVie Inc. (ABBV) is listed under Drug Manufacturers - General. Valued at $439.62B, ABBV is a mega-cap name in its sector. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Market Cap
$439.62B
Beta
0.28
P/E (TTM)
70.28
P/E (Fwd)
15.28
EPS (TTM)
$3.54
EPS (Fwd)
$16.28
ROE
—
ROA
10.5%
Cash
$6.57B
Total Debt
$70.88B
Free CF
$16.87B
52W Change
21.2%
Annual Financials
Cash vs Debt
Where ABBV stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ABBV finished 14.62% above its 150-day moving average ($226.83) and 15.39% above its 200-day moving average ($225.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABBV overbought or oversold?
At the September 2, 2026 close, ABBV's RSI(14) was 62.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $6.57B in cash, though total debt stands at $70.88B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $16.87B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $56.20B (2021) to $61.16B (2025).
ABBV's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing ABBV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.